Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipeline trouble.

Original title: “FDA scientists question Capricor data; Legend CEO steps down”

After leaving Tessera Therapeutics earlier this month, Michael Severino will take over Sarepta Therapeutics as the biotech awaits two key regulatory decisions in Duchenne muscular dystrophy.

Original title: “Sarepta names former AbbVie R&D exec Michael Severino as next CEO”

BioMarin is a biotechnology company focused on rare disease medicines, with nine commercial therapies. The n-Lorem Foundation is a nonprofit organization that develops antisense oligonucleotide medicines for patients with diseases resulting from single genetic defects. BioMarin partners with n-Lorem to develop ReNU syndrome treatment (NASDAQ:BMRN) and n-Lorem Foundation announced today a strategic collaboration and global exclusive license agreement to develop an antisense oligonucleotide medicine for ReNU syndrome, according to a press release statement. The collaboration will advance an investigational ASO candidate targeting the RNU4-2 (n.64_65insT) variant, which accounts for approximately 75% of ReNU syndrome cases. ReNU syndrome is a rare genetic neurodevelopmental condition associated with cognitive, language and adaptive behavioral impairments.

Original title: “BioMarin partners with n-Lorem to develop ReNU syndrome treatment By Investing.com”

The star of the takeover is Forte Biosciences' investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.

Original title: “Argenx deepens immuno expertise with $2.2B Forte Biosciences buy”

How can biotechs be investor ready? Key takeaways from BIO International and DIA China 2026.

Original title: “From confidence to capital: Positioning biotech for the next growth cycle”

Investment and a maturing talent base have propelled Denmark ahead of its Nordic peers, drawing Swedish companies and exposing regional gaps in capital and scale.

Original title: “Denmark’s foundation‑fueled biotech boom redraws the Nordic map”

Safety will be the key determinant of in vivo CAR T therapies, according to H.C. Wainwright’s Mitchel Kapoor, who noted that convenience and efficacy won’t be enough to impress investors in this space. Eli Lilly, AbbVie, AstraZeneca and more are up for the challenge.

Original title: “Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle”

The FDA will hold advisory committee meetings this week for previously rejected investigational therapies from Replimune and Capricor Therapeutics. Some industry leaders were surprised the meetings were called at all, while many have questioned the rationale behind them and other adcomms on deck.

Original title: “FDA has recommitted to adcomms—but to what end?”

The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster. One analyst expects Sanofi to now pursue “strategic action” to boost its pipeline.

Original title: “Sanofi halts development of troubled immune drug in eczema”

Facing pressure around the world to withdraw the rare kidney disease drug Tavneos, Amgen has launched a robust defense with real-world evidence to support the product’s benefit-risk profile.

Original title: “Amgen deploys patients to defend troubled Tavneos in FDA hearing request”

Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.

Original title: “Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma”